Charles River Laboratories International, Inc.

Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-07-17 13:01:12

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com - 2026-07-14 13:10:32

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company,

gurufocus.com - 2026-07-13 09:00:00

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA.

businesswire.com - 2026-07-13 08:00:00

The last months were eventful for Achieve Life Sciences, sending the stock strongly down, but later to a new high for the year, implying optimism about the future path. Achieve is, in my view, a more derisked case now, thanks to successful financing, progress on shifting its supply chain, and new leadership. Despite the CRL, ACHV continues to advance. The denial was not drug-related, pointing towards a possible successful outcome in this story.

seekingalpha.com - 2026-07-07 11:33:38

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

prnewswire.com - 2026-07-03 12:25:00

Investors with an interest in Medical Services stocks have likely encountered both Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?

zacks.com - 2026-07-01 12:40:29

Charles River Laboratories International, Inc. CRL is well-poised to grow in the coming quarters owing to the strength of its Research Models and Services (“RMS”) business and broader CRADL adoption. Strategic deals continue to broaden its capabilities while streamlining its portfolio.

zacks.com - 2026-07-01 10:30:52

Achieve Life Sciences remains a cytisinicline story, with very positive smoking-cessation data. This also gives cytisinicline some added optionality for vaping. The FDA's CRL appears to be mostly about manufacturing and labeling issues. However, it's not about a particular cytisinicline efficacy or safety problem. ACHV is currently targeting Q4 2026 resubmission and, assuming everything goes according to plan, it could receive approval by 1H2027.

seekingalpha.com - 2026-06-23 07:30:14

Bio-Rad Laboratories offers high profitability and a liquid balance sheet with a current ratio above 5x. Charles River Laboratories International maintains a leading scale in drug discovery services with over 19,000 employees globally.

fool.com - 2026-06-22 17:44:44

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly). TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated le.

businesswire.com - 2026-06-18 08:00:00

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

Disc Medicine (IRON) offers a differentiated hematology platform with late-stage assets, robust cash reserves, and a clear regulatory path for bitopertin. APOLLO Phase 3 trial for bitopertin in EPP/XLP is fully enrolled; data expected Q4 2026, with FDA approval decision anticipated by mid-2027. Disc's $730M cash runway extends through 2029, supporting multiple pivotal readouts without near-term dilution risk.

seekingalpha.com - 2026-06-17 10:38:38

Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX) or SpaceX IPO rush is starting to fade somewhat.

247wallst.com - 2026-06-17 08:00:44

Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

zacks.com - 2026-06-15 12:41:09

Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-03 12:12:06

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will participate in the Sidoti Small-Cap Virtual Conference on June 17 and 18, 2026. CRA Chairman and Chief Executive Officer Paul Maleh is scheduled to present at 10:00 a.m. EDT on Wednesday, June 17. A live webcast will be available on the Company's investor relations website. An archived replay will be avai.

businesswire.com - 2026-06-03 08:30:00

Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock Conference Transcript

seekingalpha.com - 2026-06-02 18:01:52

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 46th Annual Growth Stock Conference on Tue

gurufocus.com - 2026-06-01 08:00:00

Pre-Market Stock Futures: Futures are trading higher after yet another winning day for Wall Street, as all major indices finished the day higher after starting the session lower. Once again, all four indices we track for readers posted all-time highs as the AI/Data Center, Memory Chip rally continues to roll on. Healthcare and consumer stocks... Here Are Friday's Top Wall Street Analyst Research Calls: Best Buy, Cogent Communications, Dell Technologies, EPAM Systems, Federal Realty, Gap, Snowflake, Viper Energy, and More

247wallst.com - 2026-05-29 08:03:40

Valuation Assessment of Charles River Laboratories International Inc (CRL) On May 27, 2026, Charles River Laboratories International Inc (CRL) shares experience

gurufocus.com - 2026-05-27 19:40:00

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

zacks.com - 2026-05-20 10:40:34

Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to colla

gurufocus.com - 2026-05-13 09:00:00

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River's expertise in biologics and cell therapy GMP testing to support MEDIPOST's global cell therapy pipeline, starting i.

businesswire.com - 2026-05-13 08:00:00

On May 12, 2026, Charles River Laboratories International Inc (CRL) shares fell 5.2%, bringing the current price to $168.46. The stock has experienced a 52-week

gurufocus.com - 2026-05-12 01:23:00

Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

zacks.com - 2026-05-11 10:16:24

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist efficiency, and supports the reduction of animal use in nonclinical research where scientifically appropriate. By fully integrating digital pathology across the histology and pathology workflow, Charles River is com.

businesswire.com - 2026-05-11 08:00:00

Charles River Laboratories International NYSE: CRL reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chief Executive Officer Birgit Girshick.

marketbeat.com - 2026-05-09 19:05:20

Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?

zacks.com - 2026-05-08 12:41:08

Charles River Laboratories International, Inc. (NYSE:CRL) posted upbeat earnings for the first quarter, but lowered its FY2026 forecast on Thursday.

benzinga.com - 2026-05-08 11:11:01

Charles River Laboratories (NYSE: CRL) beat Q1 earnings estimates but lowered its FY2026 forecast. Analysts maintain positive outlook with raised price targets.

feeds.benzinga.com - 2026-05-08 11:11:01

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 15:21:23

Charles River Laboratories is downgraded to 'Sell' as shares have rallied 57% in the past year, outpacing fundamentals. Despite Q1 stabilization, organic revenue declined 1.5% and margins compressed, with near-term growth muted and longer-term AI and regulatory risks looming. CRL maintains 2026 EPS guidance of $10.80–$11.30 but trades at 17.5x forward earnings—still at a discount to its history but not considered cheap.

seekingalpha.com - 2026-05-07 12:26:07

Charles River beats Q1 earnings and revenue estimates, but margin declines and weak organic growth in key segments send shares lower in pre-market.

zacks.com - 2026-05-07 11:20:08

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-05-07 10:31:20

Charles River Laboratories (CRL) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $1.96 per share. This compares to earnings of $2.34 per share a year ago.

zacks.com - 2026-05-07 09:56:18

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced financial results for the fiscal first quarter ended April 4, 2026. “Maintaining the momentum of a record fiscal 2025, CRA continued its strong performance into the first quarter of fiscal 2026 as revenue increased by 10.5% year over year to $201.0 million,” said Paul Maleh, CRA's President and Chief Executive Officer. “This re.

businesswire.com - 2026-05-07 08:05:00

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial and management consulting services, today announced that its Board of Directors has declared a quarterly cash dividend of $0.57 per common share to be paid on June 12, 2026 to shareholders of record of CRA's common stock as of the close of business on May 26, 2026. The Company expects to continue paying quarterly dividends, the declaration, timing and amounts of which remain sub.

businesswire.com - 2026-05-07 08:00:00

Contract drug developer Charles River Laboratories on Thursday beat Wall Street expectations for first-quarter results, ​helped by improved demand for its drug discovery and development ‌services.

reuters.com - 2026-05-07 07:54:54

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2026 Financial Results.

businesswire.com - 2026-05-07 07:00:00

Evaluate the expected performance of Charles River (CRL) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

zacks.com - 2026-05-06 10:15:44

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-30 11:06:52

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories today announced an enhanced In Vitro Fertility (IVF) service bundle designed to accelerate rat-model programs across therapeutics areas, including oncology, neurology, cardiology, and metabolic. By leveraging embryo transfer, cryopreservation, and colony rederivation, teams can rapidly recover lines, expand cohorts, and safeguard critical genotypes—while reducing downtime caused by breeding bottlenecks. This offering pairs dedicated.

businesswire.com - 2026-04-30 08:00:00

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com - 2026-04-28 10:45:31

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the company will webcast its first-quarter 2026 financial results conference call on Thursday, May 7, 2026 at 10:00 a.m. ET. The conference call will be hosted by President and Chief Executive Officer Paul Maleh, Chief Financial Officer Eric Nierenberg, and Chief Corporate Development Officer Chad Holmes. To listen to a l.

businesswire.com - 2026-04-23 08:30:00

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has shared the results of a retrospective analysis in Regulatory Toxicology and Pharmacology, showing that virtual control groups (VCGs) can preserve scientific integrity while reducing reliance on animal models. The review, which looked at 20 toxicology studies that replaced concurrent control groups (CCGs) with curated VCGs, and compared the outcomes across study-level decisions and detailed endpoin.

businesswire.com - 2026-04-21 08:00:00